Literature DB >> 8599859

Promising new agents in the treatment of non-small cell lung cancer.

M J Edelman1, D R Gandara.   

Abstract

A number of new drugs and drug classes have recently become available for clinical testing which demonstrate significant antitumor activity in non-small cell lung cancer. The preclinical rationale, mechanism of action, toxicity profile and results of early trials of paclitaxel, docetaxel, edatrexate, CPT-11, topotecan, vinorelbine and gemcitabine in non-small cell lung cancer are reviewed.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8599859     DOI： 10.1007/s002800050402

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  46 in total

1.  Gemcitabine: current status of phase I and II trials.

Authors:  S B Kaye
Journal:  J Clin Oncol       Date:  1994-08       Impact factor: 44.544

2.  Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor.

Authors:  L Saltz; M Sirott; C Young; W Tong; D Niedzwiecki; Y Tzy-Jyun; Y Tao; B Trochanowski; P Wright; K Barbosa
Journal:  J Natl Cancer Inst       Date:  1993-09-15       Impact factor: 13.506

3.  New folate analogs of the 10-deaza-aminopterin series. Basis for structural design and biochemical and pharmacologic properties.

Authors:  F M Sirotnak; J I DeGraw; D M Moccio; L L Samuels; L J Goutas
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

4.  CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer.

Authors:  N Masuda; M Fukuoka; M Takada; Y Kusunoki; S Negoro; K Matsui; S Kudoh; N Takifuji; K Nakagawa; S Kishimoto
Journal:  J Clin Oncol       Date:  1992-11       Impact factor: 44.544

Review 5.  The National Cancer Institute: cancer drug discovery and development program.

Authors:  M R Grever; S A Schepartz; B A Chabner
Journal:  Semin Oncol       Date:  1992-12       Impact factor: 4.929

6.  Schedule-dependent synergism of edatrexate and cisplatin in combination in the A549 lung-cancer cell line as assessed by median-effect analysis.

Authors:  E A Perez; F M Hack; L M Webber; T C Chou
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 7.  Taxol: a novel investigational antimicrotubule agent.

Authors:  E K Rowinsky; L A Cazenave; R C Donehower
Journal:  J Natl Cancer Inst       Date:  1990-08-01       Impact factor: 13.506

8.  A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.

Authors:  J L Abbruzzese; R Grunewald; E A Weeks; D Gravel; T Adams; B Nowak; S Mineishi; P Tarassoff; W Satterlee; M N Raber
Journal:  J Clin Oncol       Date:  1991-03       Impact factor: 44.544

9.  In situ analysis of the action of Navelbine on various types of microtubules using immunofluorescence.

Authors:  S Binet; A Fellous; H Lataste; A Krikorian; J P Couzinier; V Meininger
Journal:  Semin Oncol       Date:  1989-04       Impact factor: 4.929

10.  Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG)

Authors:  T Cerny; S Kaplan; N Pavlidis; P Schöffski; R Epelbaum; J van Meerbeek; J Wanders; H R Franklin; S Kaye
Journal:  Br J Cancer       Date:  1994-08       Impact factor: 7.640
View more
  7 in total

1.  Quantification of chemotherapeutic target gene mRNA expression in human breast cancer biopsies: comparison of real-time reverse transcription-PCR vs. relative quantification reverse transcription-PCR utilizing DNA sequencer analysis of PCR products.

Authors:  Agnes Juhasz; Paul Frankel; Catherine Cheng; Hector Rivera; Reena Vishwanath; Alice Chiu; Kim Margolin; Yun Yen; Edward M Newman; Tim Synold; Sharon Wilczynski; Heinz-Josef Lenz; David Gandara; Kathy S Albain; Jeffrey Longmate; James H Doroshow
Journal:  J Clin Lab Anal       Date:  2003       Impact factor: 2.352

2.  Phase II study of gemcitabine and vindesine in patients with previously untreated non-resectable non-small-cell lung cancer.

Authors:  J B Sørensen; B Bergman; A L Nielsen; M Krarup; P Dombernowsky; H H Hansen
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

3.  Clinical effectiveness and clinical toxicity associated with platinum-based doublets in the first-line setting for advanced non-squamous non-small cell lung cancer in Chinese patients: a retrospective cohort study.

Authors:  Yan Wang; Jianhua Chen; Shengqi Wu; Chenping Hu; Xiaoling Li; Yuqin Wang; Yicheng Yang; Narayan Rajan; Yun Chen; Yi Chen; Zhuanzhuan Luo; Wendong Chen
Journal:  BMC Cancer       Date:  2014-12-12       Impact factor: 4.430

4.  Impact of platinum/pemetrexed combination versus other platinum-based regimens on adjuvant chemotherapy in resected lung adenocarcinoma.

Authors:  Xiaoyu Zhai; Qiwen Zheng; Lu Yang; Yixiang Zhu; Junling Li; Yutao Liu; Ziping Wang
Journal:  Sci Rep       Date:  2017-05-03       Impact factor: 4.379

5.  Anti-tumor efficacy of paclitaxel against human lung cancer xenografts.

Authors:  T Yamori; S Sato; H Chikazawa; T Kadota
Journal:  Jpn J Cancer Res       Date:  1997-12

6.  Delayed expression of apoptosis in human lymphoma cells undergoing low-dose taxol-induced mitotic stress.

Authors:  R Allman; R J Errington; P J Smith
Journal:  Br J Cancer       Date:  2003-05-19       Impact factor: 7.640

7.  Identification of microRNA profiles in docetaxel-resistant human non-small cell lung carcinoma cells (SPC-A1).

Authors:  Wang Rui; Feng Bing; Song Hai-Zhu; De Wei; Chen Long-Bang
Journal:  J Cell Mol Med       Date:  2009-11-09       Impact factor: 5.310
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.